Is Enzolytics Inc. (ENZC) a Buy, Sell, or Hold?
Enzolytics Inc.
OTC:ENZC
$0.0007 USD
$0 (0.0%)
- Volume
- 263.4K
- Average Volume
- 12.21M
- Market Capitalization
- $2.76M
- P/E Ratio
- -13.07
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.63
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Steven Sharabura |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ENZC |
| CUSIP | 294112107 |
| CIK | 0001421851 |
| Web | https://enzolytics.com |
| Phone | 972 292 9414 |
| Currency | USD |
| Employees | 1 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.63 |
| Quick Ratio | 0.63 |
| Cash Ratio | 0.00 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | 0.00 |
| Price / Cash Flow | 0.00 |
| Price / Book | -0.02 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0 |
| Trailing P/E Ratio | -13.07 |
| PEG Ratio | -0.07 |
| P/E Growth | -0.07 |
| Net Income | $-92239 |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | 0.16% |
| Return on Assets | -0.09% |
Financials Score
| AltmanZ Score | -1.76 |
| Piotroski Score | 2.00 |
| Working Capital | -119.58M |
| Total Assets | 201.66M |
| Ebit | -367.12K |
| Market Cap | 2.76M |
| Total Liabilities | 320.34M |
Poll Results
About Enzolytics Inc. (OTC:ENZC) Stock
Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The company possesses patented anti-HIV treatments that have successfully completed clinical testing. Additionally, Enzolytics has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies, intended to provide non-toxic passive immunotherapy against various infectious diseases. A significant achievement includes the creation of a proprietary cell line, specifically engineered to produce human monoclonal antibodies that effectively target and neutralize the human immunodeficiency virus (HIV). ...
Frequently Asked Questions
-
What is the current Enzolytics Inc. (ENZC) stock price?
-
Enzolytics Inc.(OTC:ENZC) stock price is $0.0007 in the last trading session. During the trading session, ENZC stock reached the peak price of $0.0013 while $0.0002 was the lowest point it dropped to. The percentage change in ENZC stock occurred in the recent session was 0.0% while the dollar amount for the price change in ENZC stock was $0.
-
ENZC's industry and sector of operation?
-
The OTC listed ENZC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ENZC?
-
Steven Sharabura | Chief Executive Officer
Diana Zhabilov | Chief Financial Officer
Charles S. Cotropia | President & Director
Harry H. Zhabilov Jr. | CSO & Chairman
| -
How many employees does ENZC have?
-
Number of ENZC employees currently stands at 1. ENZC operates from 2000 North Central Expressway, Plano, TX 75074, US.
-
Link for ENZC official website?
-
Official Website of ENZC is: https://enzolytics.com
-
How do I contact ENZC?
-
ENZC could be contacted at phone #972 292 9414 and can also be accessed through its website. ENZC operates from 2000 North Central Expressway, Plano, TX 75074, US.
-
How many shares of ENZC are traded daily?
-
The average number of ENZC shares traded daily for last 3 months was 12.21M.
-
What is the market cap of ENZC currently?
-
The market value of ENZC currently stands at $2.76M with its latest stock price at $0.0007